 |
|
|
 |
Greater Response Rates Seen In Chronic Hepatitis B Patients Treated With Combination Zadaxin And Alpha Interferon
A new study presented yesterday at the American Association for the Study of Liver Disease (AASLD) session at the Digestive Disease Week (DDW) meeting in Atlanta showed significantly greater sustained response rates in patients treated with the combination of Zadaxin(R), an immune system enhancer (ISE), and alpha interferon than those in patients treated with alpha interferon alone. more
|
|
Irbesartan Appears To Prevent Progression Of Renal Disease In Patients With Type 2 Diabetes And Hypertension
The high blood pressure drug irbesartan (Avapro(R)) can protect against kidney disease in people who have high blood pressure and Type 2 diabetes, preventing the progression of kidney disease or death by 20 percent (p=0.02) versus placebo, and 23 percent (p=0.006) versus amlodipine, according to a study reported by Dr. Edmund J. Lewis, director of nephrology at Rush-Presbyterian-St. Luke's Medical Center, Chicago. Dr. Lewis is the lead investigator of the Irbesartan Diabetic Nephropathy Trial (IDNT). more
|
|
|
|
Nighttime Heartburn Approaches Epidemic Proportions--Finding Reveals Link Between Heartburn And Respiratory Symptoms
Seventy-nine percent of the 60 million American adults who experience heartburn have symptoms at night and suffer the consequences of sleep deprivation and impaired quality of life, according to data presented today by the American Gastroenterological Association (AGA) at Digestive Disease Week(DDW). The severity of nighttime heartburn was highlighted by a study in "New England Journal of Medicine," which found that people who experience nighttime heartburn symptoms are eleven times more likely to develop esophageal cancer than those who do not. Coupled with the findings presented today on the wide reach of this condition, with an impact on (nearly 50 million) people nationwide, nighttime heartburn is becoming a major public health concern. more
|
|
In New Study Covera-HS Outperforms Vasotec and Cozaar For Effective for Morning Control of Hypertension
A new study presented today demonstrated that Covera-HS(R) (COER-verapamil), a calcium-channel blocker, taken at bedtime, produced a more significant reduction in blood pressure during the critical early morning hours than morning doses of either the leading ACE inhibitor, Vasotec(R) (enalapril) or angiotensin II receptor antagonist, Cozaar(R) (losartan). The results were presented at the Sixteenth Annual Scientific Meeting and Exposition of the American Society of Hypertension (ASH) in San Francisco, California. more
|
|
Prescribing Information: Covera-HS
Covera-HS has a unique delivery system, designed for bedtime dosing, incorporating a 4 to 5-hour delay in drug delivery. The unique controlled-onset, extended-release (COER) delivery system, which is designed for bedtime dosing, results in a maximum plasma concentration (Cmax) of verapamil in the morning hours. Verapamil is a calcium ion influx inhibitor (L-type calcium channel blocker or calcium channel antagonist). Verapamil exerts its pharmacologic effects by selectively inhibiting the transmembrane influx of ionic calcium into arterial smooth muscle as well as in conduc- tile and contractile myocardial cells without altering serum calcium concentrations. Get the full prescribing information in today's issue of Vidyya. more
|
|
|
